2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2870

Predictors of Early Minimal Disease Activity in Psa Patients Treated with Anti-TNF in a Real-World Registry
Abstract Number: 2871

Effectiveness and Safety of Golimumab in the Treatment of Ankylosing Spondylitis over a 12 Month Period
Abstract Number: 2872

Two-Year Clinical Response to Brodalumab, an Anti-Interleukin-17 Receptor Antibody, in Patients with Psoriatic Arthritis
Abstract Number: 2873

Pharmacological Treatment of Psoriatic Arthritis (PSA): Systematic Literature Review for the Update of the EULAR Recommendations for the Management of PSA
Abstract Number: 2874

Two-Years Survival of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis and Predictors Thereof in Real-Life Settings
Abstract Number: 2875

Anti-TNF Therapy Is Not Associated with an Increase in Neoplasias in Patients with Spondyloarthritis (SpA): Results from the GISEA Registry
Abstract Number: 2876

Baseline Demographic and Disease Characteristics Associated with Response to Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis
Abstract Number: 2877

What Is the Location of Enthesitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond to Anti-TNF Treatment?
Abstract Number: 2878

Treating Axial Spondyloarthritis to Target: Influence of the Population Characteristics and Comorbidities in Reaching Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease in a Cohort of Patients Treated with Tnfalpha Inhibitors Agents
Abstract Number: 2879

What Is the Location of Dactylitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond to Anti-TNF Treatment?
Abstract Number: 2880

Real-World Impact of Anti-TNF Medication Use on Patient Reported Outcomes in a Prospective Cohort of Patients with Ankylosing Spondylitis
Abstract Number: 2881

Infliximab in Spondyloarthritis Patients: Utility of Drug Level Monitoring
Abstract Number: 2882

Baseline Extent of Damage at the Spine Predicts Radiographic Progression in Korean Patients Using Golimumab for Ankylosing Spondylitis
Abstract Number: 2883

Relationship Between Improvements in Fatigue and Signs & Symptoms of Active Psoriatic: Arthritis a Sub-Analysis of a Phase 3 Study with Secukinumab
Abstract Number: 2884

Epidemiological Parameters Affecting Therapeutic Response in Psoriatic Arthritis Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].